Correlation of Tc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression.

BACKGROUND

Tc-sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) has recently been explored for the characterization of indeterminate renal masses. As judged by increased intra-tumoral radiotracer uptake, we have previously reported the excellent diagnostic performance characteristics of this test for identifying benign/indolent oncocytomas and hybrid oncocytic/chromophobe tumors (HOCTs). In this study, we investigated potential molecular mechanisms underlying the discriminatory ability of Tc-sestamibi SPECT/CT for renal masses. Fifty renal masses imaged with Tc-sestamibi SPECT/CT prior to surgical resection were evaluated by immunohistochemistry for mitochondrial content and expression of the multi-drug resistance pump 1 (MDR1/P-gp). Immunohistochemical staining was scored semi-quantitatively, and results were compared across renal tumor histologies and correlated with Tc-sestamibi uptake.

RESULTS

In total, 6/6 (100%) and 2/2 (100%) HOCTs demonstrated strong mitochondrial content staining combined with low MDR1 staining. Clear cell renal cell carcinoma showed an opposite pattern with the majority having low mitochondrial (14/26, 54%) and high MDR1 staining (18/26, 69%). Other tumor types were more variable in staining pattern, although the staining pattern reliably predicted Tc-sestamibi uptake in almost all tumors except chromophobe renal cell carcinoma.

CONCLUSIONS

Our findings confirm that renal tumors with high mitochondrial content and relatively low MDR pump expression activity accumulate Tc-sestamibi and allow for the accurate diagnosis of the benign/indolent tumor class that includes oncocytomas and HOCTs. For masses in which MDR activity outweighs the presence of mitochondria, the tumors appear cold on Tc-sestamibi SPECT/CT, allowing for high confidence in the diagnosis of renal cell carcinoma.